10x Genomics Begins Commercial Shipments of Chromium GEM-X Products

Rhea-AI Summary

10x Genomics, Inc. introduces GEM-X technology architecture, enhancing single cell analysis with improved sensitivity, scalability, cost-efficiency, and data quality. The new products, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3, offer superior performance and workflow advantages.

Biotechnology Analyst

The introduction of 10x Genomics' GEM-X technology represents a significant advancement in the field of single cell analysis. The enhanced sensitivity of detecting up to two times more genes allows for a more detailed understanding of cellular heterogeneity, which is crucial for identifying nuanced biological differences between cells. This could lead to breakthroughs in fields such as oncology, immunology and neurobiology, where understanding individual cell behavior is paramount.

Moreover, the ability to capture a higher number of cells per channel and the reduction in cost per cell are pivotal developments. They not only make the technology more accessible to a broader range of research institutions but also enable large-scale studies that were previously cost-prohibitive. The financial implications for 10x Genomics are potentially substantial as these improvements could drive increased adoption of their technology and provide a competitive edge in the market.

However, challenges remain in the scalability of such technologies and the interpretation of the vast amounts of data generated. The biotechnology industry continues to grapple with the need for advanced computational tools and expertise to handle this data, which could be a limiting factor in the widespread application of GEM-X.

Market Research Analyst

The release of GEM-X technology by 10x Genomics is poised to disrupt the single cell analysis market. The doubling of gene detection and the increased cell capture capacity are likely to be received positively by the research community, which has been seeking more efficient and cost-effective solutions in single cell sequencing.

From a market perspective, this innovation could lead to an expansion of the single cell analysis market size, as it lowers the barriers to entry for researchers with limited budgets. The cost reduction and improved data quality are critical factors that can influence purchasing decisions and potentially increase the market share for 10x Genomics. This development could also put pressure on competitors to accelerate their own technological advancements, leading to an innovation race within the sector.

It is important to monitor how this technology is adopted in the market and the subsequent impact on 10x Genomics' financial performance, particularly in terms of revenue growth and market penetration. The company's ability to capitalize on this innovation and convert it into a sustainable competitive advantage will be key to its long-term success.

Healthcare Industry Analyst

The GEM-X technology's enhanced assay robustness and increased sample recovery are particularly relevant for the healthcare industry, where the quality and efficiency of sample analysis can directly impact clinical research outcomes. The improved recovery rate of up to 80% for cells is especially beneficial for precious or limited samples, such as those obtained from tissue biopsies, which are common in clinical settings.

With the potential for more accurate and comprehensive data, researchers could make more informed decisions in areas such as precision medicine and patient stratification. This could eventually lead to more targeted therapies and personalized treatment plans. The long-term implications for healthcare could be profound, as these technologies enable a deeper understanding of disease mechanisms at the cellular level.

However, it is crucial to consider the regulatory landscape and the speed at which such technological advancements can be translated into clinical practice. The adoption of GEM-X in clinical research will depend on regulatory approvals and the demonstration of clear clinical benefits over existing technologies.

The next generation of the company's leading single cell technology architecture, GEM-X, enables higher performance at larger scale and lower cost

PLEASANTON, Calif., March 13, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3. GEM-X is the next generation of the company's leading single cell technology architecture and is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized reagents for superior performance and high reliability.

"It's been incredible to see the enthusiasm from customers since we first announced the GEM-X architecture last month, and we can't wait to get these new products in researchers' hands," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer of 10x Genomics. "GEM-X sets a new standard for single cell analysis and gives customers important performance advantages that will immediately benefit their research. This is one of multiple steps we have planned to make single cell more accessible for all."

GEM-X is exclusively available for use on Chromium X Series instruments and delivers important performance and workflow advantages, including:

• Substantially increased sensitivity: Detect up to two times more genes compared to on-market Chromium assays to gain a more comprehensive view of cellular heterogeneity
• Built to scale: Two-fold increase in cells captured per channel
• More cost effective: More than two-fold reduction in cost per cell
• Enhanced data quality: Two-fold reduction in multiplet rate enabling high quality data at scale
• Maximum sample recovery: Recovery of up to 80% of cells, improving capture efficiency and making it ideal for samples typically yielding few cells, such as tissue biopsies or previously flow sorted cells
• Improved assay robustness: Redesigned microfluidics and optimized reagents for faster and more efficient cell partitioning

"Selecting the optimal assay for single-cell experiments is challenging. However, it's evident that identifying more genes per cell enriches our understanding of cellular functions and the intricacies of biology," said Luciano Martelotto, Associate Professor at the University of Adelaide. "GEM-X, with its exceptional transcript capture, can enhance our capacity to differentiate cell types, spot rare cells and decode regulatory pathways. Improved accuracy in transcriptome data further facilitates the seamless integration of single-cell findings from diverse research projects and platforms."

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s ("10x Genomics") product launches, performance, configuration, costs, capabilities, adoption and pipeline. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.

Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-begins-commercial-shipments-of-chromium-gem-x-products-302088504.html

SOURCE 10x Genomics, Inc

What is the new technology architecture introduced by 10x Genomics, Inc.?

10x Genomics, Inc. introduced the GEM-X technology architecture, the next generation of its leading single cell technology.

What are the first two products powered by the GEM-X technology architecture?

The first two products powered by the GEM-X technology architecture are Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3.

What are the key advantages of GEM-X technology?

The key advantages of GEM-X technology include substantially increased sensitivity, scalability, cost-effectiveness, enhanced data quality, maximum sample recovery, and improved assay robustness.

Who is Michael Schnall-Levin?

Michael Schnall-Levin is the Founding Scientist and Chief Technology Officer of 10x Genomics.

What benefits does GEM-X technology offer for single-cell experiments?

GEM-X technology enriches understanding of cellular functions, differentiates cell types, spots rare cells, decodes regulatory pathways, and facilitates seamless integration of single-cell findings.